Xenetic Biosciences to acquire Santersus in all-stock exchange
Xenetic Biosciences entered a definitive all-stock share exchange to acquire Santersus, with pro forma ownership of ~15% for Xenetic holders and ~85% for Santersus holders, subject to approvals.
Story updates
11:02:15 AM UTC
SquawkNews
Xenetic Biosciences entered a definitive all-stock share exchange to acquire Santersus, with pro forma ownership of ~15% Xenetic holders and ~85% Santersus holders, subject to approvals. The combined company is expected to trade on Nasdaq as Santersus Bio.Material DetailsContext by AI AnalystThis i…
11:03:47 AM UTC
SquawkNews
Xenetic Biosciences signed a Share Exchange Agreement to acquire Santersus in an all-stock transaction intended to be tax-free. At closing, Santersus shareholders will receive Xenetic common stock based on a defined exchange ratio, and Santersus options will be assumed. Concurrently, Xenetic invest…
11:07:59 AM UTC
SquawkNews
Xenetic Biosciences in Reverse Merger Pact With Santersus AG >XBIO
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.